Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinnarizine for behavioral symptoms in children with autism
IRCT20110628006907N16Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Cinnarizine with Placebo (2 arms). Primary endpoint: Behavioral problems questionnaire score. Started Jan 2022; status: completed.
02
Drugs
cinnarizine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20110628006907N16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20110628006907N16.